COVID-19
South Korea-based vaccine and biotech company SK bioscience has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1/2 clinical trial of a new influenza vaccine candidate, NBP607B. This candidate incorporates an adjuvant into its existing cell-based influenza vaccine,
COVID-19
The global Flu RNA Vaccines market is emerging as a transformative segment in the broader influenza prevention landscape, driven by the success of mRNA platforms during the COVID-19 pandemic and the increasing demand for faster, scalable, and more effective vaccine technologies. The market is expected to grow significantly, reaching $7.
COVID-19
Research conducted at University Hospital Strasbourg, France, has revealed a potential link between vaccination and a decreased severity of COVID-19 in patients with inflammatory rheumatic diseases. The study, published in the journal Vaccine, compared the COVID-19 severity among patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis who were vaccinated against
B cells
New research out of Kyung Hee University in Seoul, South Korea, has shed light on a novel approach to influenza vaccine delivery, indicating that orally dissolving films (ODFs) may be a more effective method than traditional oral administration. This innovative strategy leverages the mucosal immune system to stimulate a robust
Diseases
During the 2023-2024 influenza season, sustained elevated activity was observed from December 2023 to February 2024, with continued activity through May 2024. Multiple influenza viruses, including A(H1N1), A(H3N2), and B, circulated during the season. Researchers from the U.S. Centers for Disease Control and Prevention conducted a study
COVID-19
Researchers at the University of Cambridge have conducted a comprehensive review of Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. The study found that both vaccines utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed
COVID-19
Researchers from Hyogo Medical University in Japan conducted a study to evaluate the humoral and cell-mediated immune responses induced by an inactivated influenza vaccine (IIV4) during the 2019/2020 influenza season. The study, which was supported by the Hyogo Medical University Grant For Research Promotion and the Japan Society For
COVID-19
A new study examining the vaccination compliance of Israeli nurses during the COVID-19 pandemic has found a significantly higher rate of COVID-19 vaccination compared to flu vaccination. The research, conducted by Ola Ali-Saleh and colleagues at Max Stern Yezreel Valley College, discovered that factors such as perceived susceptibility, perceived severity,
COVID-19
Results from the initial cohort of Novavax's COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza vaccine candidates have shown both vaccines induced robust immune responses and were well tolerated in adults aged 65 and older. The Phase 3 trial was designed to provide descriptive data on three
Child health
Researchers in South Korea have recently published data on cell culture-derived influenza vaccines, specifically the SKYCellflu quadrivalent vaccine. The study aimed to assess the safety and influenza infections in children aged 6-35 months following SKYCellflu vaccination. The prospective cohort, non-interventional, multi-center post-marketing surveillance study was conducted from 2020 to 2024,
COVID-19
The winter months bring a heightened risk of respiratory illnesses, including influenza, COVID-19, and respiratory syncytial virus (RSV). Immunizations are available for these illnesses, and it's essential to take preventive measures to protect yourself and others. Young children and older adults are particularly vulnerable to severe illness, requiring
Adults
Researchers from Otto-von-Guericke-University in Magdeburg, Germany, have conducted a phase 3 trial to evaluate the safety, tolerability, and immunogenicity of an adjuvanted H5N1 vaccine in adults with and without underlying immunosuppressive conditions. The study, published in the journal Vaccines, demonstrates the efficacy of the vaccine in inducing antibody responses in
